Form 4: INBP Insider Transfers Shares Posthumously

A Form 4 filing reveals the posthumous transfer of over 1.3 million Integrated BioPharma shares by Carl DeSantis's estate to an entity controlled by Damon DeSantis.

Summary

• Carl DeSantis, a deceased Director and 10% owner of Integrated BioPharma Inc. (INBP), had shares transferred on March 24, 2026.
• 1,356,293 shares of Common Stock were transferred from CD Financial, LLC to CDDS 2.0, LLC, an entity controlled by Damon DeSantis.
• An additional 7,392 shares of Common Stock were transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC.
• Both transfers were reported with a transaction price of $0, indicating they were gifts or estate distributions.
• Following these transactions, the indirect beneficial ownership attributed to the reporting person's estate and related entities is 11,366,673 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a mandatory disclosure of share transfers related to estate matters rather than a strategic or operational development for the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those related to estate matters, are common disclosures and typically do not reflect operational or strategic shifts within the biopharma industry.

Related Party Transactions

• Transfers of shares occurred between entities (CD Financial, LLC and Carl DeSantis Revocable Trust) and CDDS 2.0, LLC, all controlled by or related to the DeSantis family, indicating related party dealings.

Stakeholder Impact

• Shareholders: The transfers represent a shift in indirect beneficial ownership within the DeSantis family, but do not dilute existing shareholders or change the overall outstanding share count.

Key Dates

Keywords

Integrated BioPharma, INBP, Carl DeSantis, Damon DeSantis, SEC Form 4, Insider Transaction, Share Transfer, Estate Planning, Beneficial Ownership